C12Y 306/01005
Apyrase , i.e. atp diphosphohydrolase
Official title: Apyrase (3.6.1.5), i.e. ATP diphosphohydrolase
C12Y306/01005 (Apyrase , i.e. atp diphosphohydrolase) appears on 29 US grants and 66 published applications in this corpus.
Search patents in C12Y- Granted patents
- 29
- Published applications
- 66
- Assignees
- 38
- Inventors
- 144
- Latest grant
- 30 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 1 | 0 |
| 2002 | 0 | 1 |
| 2003 | 0 | 1 |
| 2004 | 1 | 1 |
| 2005 | 0 | 1 |
| 2006 | 0 | 1 |
| 2007 | 0 | 0 |
| 2008 | 1 | 1 |
| 2009 | 0 | 3 |
| 2010 | 0 | 1 |
| 2011 | 1 | 1 |
| 2012 | 0 | 1 |
| 2013 | 1 | 2 |
| 2014 | 1 | 1 |
| 2015 | 0 | 4 |
| 2016 | 0 | 2 |
| 2017 | 0 | 5 |
| 2018 | 3 | 1 |
| 2019 | 2 | 2 |
| 2020 | 0 | 3 |
| 2021 | 3 | 2 |
| 2022 | 3 | 8 |
| 2023 | 3 | 10 |
| 2024 | 2 | 6 |
| 2025 | 2 | 3 |
| 2026 | 4 | 5 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Combination treatment by administering a recombinant apyrase protein in conjunction with a P2Y12 inhibitor30 Jun 2026US 12,668,785 B2AstraZeneca AB
- Cells, tissues, organs, and animals having one or more modified genes for enhanced xenograft survival and tolerance26 May 2026US 12,637,690 B2eGenesis, Inc.
- Cells, tissues, organs, and animals having one or more modified genes for enhanced xenograft survival and tolerance19 May 2026US 12,630,838 B2eGenesis, Inc.
- Universal donor cells24 Feb 2026US 12,559,726 B2Crispr Therapeutics AG
- Solubilized apyrases, methods and use10 Jun 2025US 12,325,870 B2Novartis AG
- Expression construct25 Jun 2026US 2026/0176598 A1Quell Therapeutics Limited
- Recombinant apyrase protein for use in the treatment of an ischemic event at a dose of 40-240 mg4 Jun 2026US 2026/0151462 A1AstraZeneca AB
- Cells, tissues, organs, and animals having one or more modified genes for enhanced xenograft survival and tolerance9 Apr 2026US 2026/0098278 A1eGenesis, Inc.
- Expression systems for phosphatases19 Feb 2026US 2026/0049323 A1International N&H Denmark Aps
- Cd39 and cd73 for the therapy of hemorrhagic shock12 Feb 2026US 2026/0041741 A1The Trustees of Columbia University in the City of New York
Most cited
By later US patents
- Method for increasing the activity of the immune system of a mammal at risk of inflammatory diseases10US 8,784,805 B2Alloksys Life Sciences B.V. · 2014
- Universal donor cells6US 11,566,230 B2Crispr Therapeutics AG · 2023
- Universal donor cells6US 11,578,309 B2Crispr Therapeutics AG · 2023
- ATP-diphosphohydrolases5US 5,798,241 AUniversite de Sherbrooke · 1998
- Apyrase therapy for bleeding conditions5US 8,535,662 B2APT Therapeutics, Inc. · 2013